GlassScriptPhysician profile
Frank R Burns
NPI 1881703924
$7,664.88
in general payments reported to CMS, 2019-2025
30 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,456 · 2020: $410 · 2021: $2,975 · 2022: $609 · 2023: $767 · 2024: $996 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,215.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $2,645.65 | 2020-2024 | Tecnis Iol, Tecnis Simplicity |
| Alcon Vision LLC | $1,162.14 | 2019-2025 | Clareon, Rocklatan, Clareon Panoptix Pro |
| New World Medical,INC. | $514.70 | 2022-2025 | Kahook Dual Blade, Streamline, Clearpath |
| Aerie Pharmaceuticals, INC. | $442.22 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $367.77 | 2019-2023 | Eylea Hd |
| Glaukos Corporation | $297.59 | 2019-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Sun Pharmaceutical Industries INC. | $212.28 | 2019-2020 | |
| Allergan, INC. | $202.93 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $174.95 | 2019 | |
| Novartis Pharmaceuticals Corporation | $163.46 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $154.48 | 2019-2021 | |
| Ellexiscience | $132.39 | 2019 | |
| Horizon Therapeutics Plc | $124.74 | 2021 | |
| Genentech, INC. | $122.38 | 2021 | |
| Astellas Pharma US INC | $120.84 | 2024 | Izervay |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $119.74 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $119.70 | 2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $116.26 | 2024 | Miebo |
| Beaver-Visitec International, INC. | $98.11 | 2021 | |
| Oyster Point Pharma, INC. | $75.41 | 2022-2024 | Tyrvaya |
| Ocular Therapeutix, INC. | $60.66 | 2023-2025 | Dextenza |
| Shire North American Group INC | $41.71 | 2019 | |
| Eyevance Pharmaceuticals LLC | $33.54 | 2019 | |
| Alcon Research LLC | $32.99 | 2019 | |
| Abbvie INC. | $32.38 | 2022-2024 | |
| Biotissue Holdings INC. | $25.74 | 2019-2020 | |
| Dompe US, INC. | $25.48 | 2025 | Oxervate |
| Rxsight INC | $19.43 | 2022 | |
| Acacia Pharma INC | $13.22 | 2021 | |
| Ivantis, INC | $11.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Burns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.